... retrospectively reviewed the medical records of the patients diagnosed with recurrent or metastatic HNACC. We compared the survival outcomes, including survival time from recurrence/metastasis (OS) patients who received systemic chemotherapy with paclitaxel (200 mg/m 2 ) and carboplatin (area under the curve 6...

...Jane E. Rogers; Xuemei Wang; Allison Trail; Jaffer A. Ajani Background: Platinum + fluoropyrimidine is a standard front-line therapy for unresectable gastroesophageal adenocarcinoma (GA). Subsequent therapy recommendations are ramucirumab + paclitaxel (RAM/PAC), taxane, irinotecan, or trifluridine...

... of paclitaxel (PTX) combined with S-1 and intravenous PTX over conventional systemic chemotherapy was suggested in a phase III study, although the difference in overall survival did not reach statistical significance in the primary analysis. Thus, attempts to combine IP PTX with other systemic therapies...

...Jane E. Rogers; Lianchun Xiao; Fatemeh G. Amlashi; Elena Elimova; Mariela A. Blum Murphy; Elizabeth Sanders; Namita Shanbhag; Irene Thomas; Jaffer A. Ajani Background: The RAINBOW trial established ramucirumab combined with paclitaxel as a second-line option in metastatic gastric...

... evaluate the activity of an association of 1G3-Cu with 5 cytotoxic agents used in chemotherapy having different modes of action. Data show no additive effect with camptothecin and cisplatin, additivity with paclitaxel and MG132, and synergy with doxorubicin. Results suggest that the multivalent Cu...

... every 10 days as a single agent in recurrent ovarian cancer after 3 prior regimens. Method: Trabectedin 0.6 mg/m 2 was administered as a 3-h infusion every 10 days on a 21-day cycle. The study population was compared to patients treated with weekly paclitaxel 80 mg/m 2 intravenously on days 1, 8, 15...

... cycles of intravenous paclitaxel 60 mg/m 2 plus cisplatin 60 mg/m 2 every 10 days; patients were then submitted to radical hysterectomy and pelvic lymphadenectomy. Results: From January 2011 to March 2013, 22 patients were enrolled. Median age was 47 (26-83) years. FIGO stages included 1 IIA, 15 IIB, 1...

...-based chemotherapy in patients with advanced urothelial cancer is limited. Based on encouraging preclinical and clinical phase I data, we evaluated the safety and efficacy of the combination of paclitaxel and everolimus in these patients. Methods: In this trial, patients having failed to respond...

...Richard Kim; Jennifer Byer; William J. Fulp; Amit Mahipal; William Dinwoodie; David Shibata Background: The development of distant metastases of squamous cell carcinoma of the anal canal (SCCA) is rare but has a poor prognosis. A combination of carboplatin and paclitaxel is commonly used...

... 2 and cyclophosphamide 600 mg/m 2 (AC) administered intravenously on day 1 every 3 weeks were followed by 12 courses of weekly paclitaxel 80 mg/m 2 , prior to radiation therapy and surgery. Although the method of premedication was left to the judgment of each investigator, administration of 5-HT3...

... combination of doxorubicin and paclitaxel (AT) for 3 cycles. Methods: Chemo-naïve women with breast cancer receiving doxorubicin (60 mg/m 2 ) and paclitaxel (200 mg/m 2 ) were eligible. Patients received palonosetron 0.25 mg intravenously before chemotherapy, however, all patients also received...

... cell lung cancers. Genetic silencing of ABCA3 in the NSCLC cell line models A549, NCI-H1650 and NCI-H1975 significantly increased tumor cell susceptibility to the cytostatic effects of both cisplatin (in all cell lines) and paclitaxel (in two of three cell lines). Taken together, ABCA3 emerges...

... considered eligible. Results: Overall, 8 articles (11 pregnancies, 12 newborns) were retrieved for paclitaxel and 1 for docetaxel (1 pregnancy, 1 newborn). In 92.31% of cases a healthy child was born, with a median follow-up of 20 months. The mean weight of the babies at delivery was 2,381 g. One study...

... or had stable disease after receiving 3 cycles of induction chemotherapy (gemcitabine and cisplatin, or paclitaxel and carboplatin) were enrolled for a prospective study of intermittent chemotherapy. We evaluated for the duration of chemotherapy holiday, toxicity, quality of life (QOL), and overall...

...Aristotle Bamias; Christina Bamia; Alexandra Karadimou; Nikolaos Soupos; Flora Zagouri; Alexandros Rodolakis; Dimitrios Haidopoulos; George Vlahos; Nikos Thomakos; Aristidis Antsaklis; Meletios A. Dimopoulos Objective: We investigated the efficacy of risk-adapted adjuvant paclitaxel/carboplatin...

...Ayako Mizota; Kohei Shitara; Chihiro Kondo; Motoo Nomura; Tomoya Yokota; Daisuke Takahari; Takashi Ura; Kei Muro Objective: To retrospectively compare docetaxel (DTX) with paclitaxel (PTX) with regard to efficacy and safety in advanced or recurrent esophageal cancer patients who previously received...

...H. Iwase; M. Shimada; T. Tsuzuki; K. Ina; M. Sugihara; J. Haruta; M. Shinoda; T. Kumada; H. Goto Objectives: To carry out a phase II multi-center study on the efficacy and safety of triple combination therapy with paclitaxel, S-1, and cisplatin in patients with unresectable/metastatic gastric...

...Hironori Ishigami; Joji Kitayama; Shoichi Kaisaki; Hironori Yamaguchi; Hiroharu Yamashita; Shigenobu Emoto; Hirokazu Nagawa Objectives: A phase I study of biweekly intravenous (IV) paclitaxel (PTX) plus intraperitoneal (IP) cisplatin (CDDP) and PTX was performed to determine the maximum tolerated...

... activity as monotherapy and in combination with chemotherapy in HER2-overexpressing metastatic breast cancer (MBC). Methods: This phase II single-arm trial assessed the safety and efficacy of first-line lapatinib in combination with paclitaxel in previously untreated patients with HER2-overexpressing MBC...

... not discerned a similar impact on patient overall survival (OS). Methods: We examined the long-term PFS and OS of a previous study population consecutively treated with either 3 cycles (group A; n = 13 patients) or 12 cycles (group B; n = 13) of paclitaxel (135 mg/m 2 ; Q21 days) maintenance therapy. Eligible...